Small nucleolar RNA host gene 25 is a long non-coding RNA helps diagnose and predict outcomes in prostate cancer

Q3 Medicine

Cancer treatment and research communications Pub Date : 2023-01-01 DOI:10.1016/j.ctarc.2023.100687

Zhang Zhiyu , Zhou Qi , Song Zhen , Zhang Jianglei , Ouyang Jun

{"title":"Small nucleolar RNA host gene 25 is a long non-coding RNA helps diagnose and predict outcomes in prostate cancer","authors":"Zhang Zhiyu , Zhou Qi , Song Zhen , Zhang Jianglei , Ouyang Jun","doi":"10.1016/j.ctarc.2023.100687","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The role of a long non-coding RNA called small nucleolar RNA host gene 25 <strong>(</strong>SNHG25) has been studied in some tumor types but the correlation between SNHG25 and PCA remains unknown.</p></div><div><h3>Methods</h3><p>The relationship between clinicopathologic characteristics and SNHG25 expression was evaluated using The Cancer Genome Atlas data. The binary classifier value of SNHG25 was calculated using areas under receiver operating characteristic (ROC) curves. Outcomes were evaluated using Kaplan-Meier and Cox regression analyses. Gene set enrichment was performed to identify potential SNHG25 functions.</p></div><div><h3>Results</h3><p>SNHG25 expression was significantly increased in PCA and correlated with age, primary therapy outcome, N stage, Gleason score, and residual tumor (<em>p</em> < 0.05). ROC curves demonstrated the effect of SNHG25 on diagnosis and outcomes (area under the curve = 0.923). Higher SNHG25 expression predicted shorter progression-free interval (PFI) (<em>p</em> < 0.001), and Cox regression showed that SNHG25 expression was an independent risk factor for reduced PFI (<em>p</em> = 0.028). SNHG25 expression was associated with mRNA and protein metabolism.</p></div><div><h3>Conclusions</h3><p>SNHG25 expression increases significantly in PCA and is negatively associated with PFI. It is a potential diagnostic and prognostic biomarker in PCA.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294223000084","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Background

The role of a long non-coding RNA called small nucleolar RNA host gene 25 (SNHG25) has been studied in some tumor types but the correlation between SNHG25 and PCA remains unknown.

Methods

The relationship between clinicopathologic characteristics and SNHG25 expression was evaluated using The Cancer Genome Atlas data. The binary classifier value of SNHG25 was calculated using areas under receiver operating characteristic (ROC) curves. Outcomes were evaluated using Kaplan-Meier and Cox regression analyses. Gene set enrichment was performed to identify potential SNHG25 functions.

Results

SNHG25 expression was significantly increased in PCA and correlated with age, primary therapy outcome, N stage, Gleason score, and residual tumor (p < 0.05). ROC curves demonstrated the effect of SNHG25 on diagnosis and outcomes (area under the curve = 0.923). Higher SNHG25 expression predicted shorter progression-free interval (PFI) (p < 0.001), and Cox regression showed that SNHG25 expression was an independent risk factor for reduced PFI (p = 0.028). SNHG25 expression was associated with mRNA and protein metabolism.

Conclusions

SNHG25 expression increases significantly in PCA and is negatively associated with PFI. It is a potential diagnostic and prognostic biomarker in PCA.

查看原文本刊更多论文

小核仁RNA宿主基因25是一种长链非编码RNA，有助于诊断和预测前列腺癌的预后

背景一种名为小核仁RNA宿主基因25（SNHG25）的长非编码RNA在某些肿瘤类型中的作用已被研究，但SNHG25与PCA之间的相关性尚不清楚。方法应用癌症基因组图谱数据分析临床病理特征与SNHG25表达的关系。SNHG25的二进制分类器值是使用受试者工作特性（ROC）曲线下的面积来计算的。使用Kaplan-Meier和Cox回归分析评估结果。进行基因集富集以鉴定潜在的SNHG25功能。结果PCA中SNHG25的表达显著增加，并与年龄、初次治疗结果、N分期、Gleason评分和残留肿瘤相关（p＜0.05）。ROC曲线显示了SNHG25对诊断和结果的影响（曲线下面积=0.923）。SNHG25表达越高，无进展间期（PFI）越短（p＜0.001），Cox回归分析表明，SNHG25的表达是PFI降低的独立危险因素（p=0.028）。结论sSNHG25在PCA中的表达显著增加，并与PFI呈负相关。它是PCA中一种潜在的诊断和预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.